IP CONTROL ADMISSION SYSTEM

ISO 27001 Control. Zero-Conflict Supplement IP Security.

Olympia Biosciences™ assesses the project scope, information-security requirements, regulatory route and transfer terms before technical disclosure.

MANDATORY ENTRY CONDITION

PAID DUE DILIGENCE

FILTER INTENSITY

LOW-INTENT MANDATES DECLINED

INITIATE R&D DUE DILIGENCE DATA ROOM / LEGAL HUB →

STRUCTURAL THREAT MODEL

Most Formula Losses Start With Incentive Failures, Not Hackers.

The highest-probability breach in supplement manufacturing is economic: a producer that can monetize adjacent formulas through private-label channels. Our architecture removes that conflict before technical work begins, then layers audited legal and data controls.

REJECTION CRITERIA

PRICE-FIRST PROCUREMENTS WITHOUT CLINICAL OR STRATEGIC THESIS
PRIVATE-LABEL REQUESTS DISGUISED AS INNOVATION MANDATES
TEAMS SEEKING FREE SCOPING OR SPECULATIVE QUOTING
PROGRAMS WITHOUT OWNER FOR REGULATORY AND CLAIM GOVERNANCE

ADMISSION TRIGGER

No Free Scoping. No Open Intake. No Low-MOQ Private Label.

The due diligence gate protects active partners from speculative demand and preserves team bandwidth for defensible mandates only.

ADMISSION REQUIREMENTS

BOARD SPONSOR WITH BUDGET AUTHORITY AND EXECUTION TIMELINE

DEFENSIBLE EBM OR TRANSFER THESIS WITH MEASURABLE MOAT TARGET

Analytical release is defined in the product specification and agreed scope.

COMMITMENT TO START WITH PAID DUE DILIGENCE

IP Security Control Matrix
CONTROL LAYER	ENFORCEMENT STANDARD	BOARD-LEVEL IMPACT
LEGAL ACCESS CONTROL	NDA BEFORE TECHNICAL DISCLOSURE	THESIS LEAKAGE BLOCKED BEFORE FIRST DATA EXCHANGE
DATA SEGMENTATION	ISO 27001 ROLE-BASED ACCESS	FORMULA FILES TRACEABLE, LOGGED, AND RESTRICTED
CONFLICT ELIMINATION	NO BRANDS OF OUR OWN	NO STRUCTURAL INCENTIVE TO CLONE CLIENT FORMULAS
IP TRANSFER FRAME	After full payment and acceptance, the rights to the formulation transfer to you in full.	DOSSIER BECOMES TRANSACTION-GRADE BALANCE-SHEET ASSET

SCROLL HORIZONTALLY TO REVIEW FULL CONTROL SURFACE

FINAL ADMISSION CHECK

If Your Mandate Is Defensible, Enter. If Not, We Decline.

Olympia Biosciences™ is built for enterprise operators, PE-backed teams, and medical leaders who treat formulation secrecy as valuation infrastructure.

INITIATE R&D DUE DILIGENCE DATA ROOM / LEGAL HUB →

Frequently Asked Questions

Why does Olympia enforce a paid admission gate before production scoping?

Because open intake destroys security architecture. The admission gate verifies mandate quality, ownership discipline, and governance readiness before any formulation intelligence is exposed.

What exactly is delivered in the R&D due diligence phase?

A go or no-go board package: threat map, transfer-risk framing, control-surface design, regulatory pressure points, and execution verdict. It is an operational decision framework, not a sales call.

How do you make formula leakage structurally improbable over long cooperation?

Through segmented access, immutable trace logs, role-bound data handling, and a no-consumer-brand operating model. Security is enforced by architecture and incentives, not declarations.

Who owns the final formulation intelligence and dossier outputs?

The client. Final specifications, release logic, and supporting documentation transfer under contractual IP ownership terms for enterprise continuity and valuation readiness.

Can low-MOQ private-label inquiries bypass this gate?

No. Low-MOQ private-label inquiries below our minimum run are filtered out. Large production orders at or above our minimum run, including softgel programmes, are welcome; IP terms are set in the contract.

How are rights, confidentiality and deliverables defined for an enterprise project?

We do not monetize your idea twice. We secure, engineer, and transfer defensible formulation assets under audited controls.

RELATED INTELLIGENCE

Proprietary Encapsulation TechnologyDefensible trade secret formulations — liposomal and micellar systemsEXPLORE ›Production Formats & MOQ ReferenceHard capsules 150K, softgels 300K, sachets 75K — your MOQ, your MBR, your formula protected under ISO 27001EXPLORE ›Physician Supplement Brand CDMOZero conflict of interest — we never own consumer brands competing with yoursEXPLORE ›CDMO vs. Private Label: IP Ownership ComparisonWhy true CDMO matters for formula exclusivity and brand valuationEXPLORE ›10 Evidence-Based CDMO Security AdvantagesQuantified IP protection vs. standard contract manufacturersEXPLORE ›Science-First Manifesto — The IP Trust FrameworkOur founding doctrine: your formulation data is your most valuable assetEXPLORE ›